297 related articles for article (PubMed ID: 24631944)
1. S100A9 and EGFR gene signatures predict disease progression in muscle invasive bladder cancer patients after chemotherapy.
Kim WT; Kim J; Yan C; Jeong P; Choi SY; Lee OJ; Chae YB; Yun SJ; Lee SC; Kim WJ
Ann Oncol; 2014 May; 25(5):974-9. PubMed ID: 24631944
[TBL] [Abstract][Full Text] [Related]
2. Gene expression and prognosis in bladder cancer--real progress? Editorial on 'S100A9 and EGFR gene signatures predict disease progression in muscle invasive bladder cancer patients after chemotherapy'.
Symanowski JT; Kim ES
Ann Oncol; 2014 May; 25(5):919-20. PubMed ID: 24608197
[No Abstract] [Full Text] [Related]
3. Epidermal growth factor expression as a predictor of chemotherapeutic resistance in muscle-invasive bladder cancer.
Mansour AM; Abdelrahim M; Laymon M; Elsherbeeny M; Sultan M; Shokeir A; Mosbah A; Abol-Enein H; Awadalla A; Cho E; Sairam V; Park TD; Shahid M; Kim J
BMC Urol; 2018 Nov; 18(1):100. PubMed ID: 30413194
[TBL] [Abstract][Full Text] [Related]
4. Comparison of mRNA, Protein, and Urinary Nucleic Acid Levels of S100A8 and S100A9 between Prostate Cancer and BPH.
Yun SJ; Yan C; Jeong P; Kang HW; Kim YH; Kim EA; Lee OJ; Kim WT; Moon SK; Kim IY; Choi YH; Kim WJ
Ann Surg Oncol; 2015 Jul; 22(7):2439-45. PubMed ID: 25348783
[TBL] [Abstract][Full Text] [Related]
5. Prognostic Impact of a 12-gene Progression Score in Non-muscle-invasive Bladder Cancer: A Prospective Multicentre Validation Study.
Dyrskjøt L; Reinert T; Algaba F; Christensen E; Nieboer D; Hermann GG; Mogensen K; Beukers W; Marquez M; Segersten U; Høyer S; Ulhøi BP; Hartmann A; Stöhr R; Wach S; Nawroth R; Schwamborn K; Tulic C; Simic T; Junker K; Harving N; Petersen AC; Jensen JB; Keck B; Grimm MO; Horstmann M; Maurer T; Steyerberg EW; Zwarthoff EC; Real FX; Malats N; Malmström PU; Ørntoft TF
Eur Urol; 2017 Sep; 72(3):461-469. PubMed ID: 28583312
[TBL] [Abstract][Full Text] [Related]
6. A DDX31/Mutant-p53/EGFR Axis Promotes Multistep Progression of Muscle-Invasive Bladder Cancer.
Daizumoto K; Yoshimaru T; Matsushita Y; Fukawa T; Uehara H; Ono M; Komatsu M; Kanayama HO; Katagiri T
Cancer Res; 2018 May; 78(9):2233-2247. PubMed ID: 29440146
[TBL] [Abstract][Full Text] [Related]
7. Maspin enhances cisplatin chemosensitivity in bladder cancer T24 and 5637 cells and correlates with prognosis of muscle-invasive bladder cancer patients receiving cisplatin based neoadjuvant chemotherapy.
Chen J; Wang L; Tang Y; Gong G; Liu L; Chen M; Chen Z; Cui Y; Li C; Cheng X; Qi L; Zu X
J Exp Clin Cancer Res; 2016 Jan; 35():2. PubMed ID: 26733306
[TBL] [Abstract][Full Text] [Related]
8. Expression of the epidermal growth factor receptor and Her-2 are predictors of favorable outcome and reduced complete response rates, respectively, in patients with muscle-invading bladder cancers treated by concurrent radiation and cisplatin-based chemotherapy: a report from the Radiation Therapy Oncology Group.
Chakravarti A; Winter K; Wu CL; Kaufman D; Hammond E; Parliament M; Tester W; Hagan M; Grignon D; Heney N; Pollack A; Sandler H; Shipley W
Int J Radiat Oncol Biol Phys; 2005 Jun; 62(2):309-17. PubMed ID: 15890569
[TBL] [Abstract][Full Text] [Related]
9. Triple-marker immunohistochemical assessment of muscle-invasive bladder cancer: Is there prognostic significance?
Labban M; Najdi J; Mukherji D; Abou-Kheir W; Tabbarah A; El-Hajj A
Cancer Rep (Hoboken); 2021 Apr; 4(2):e1313. PubMed ID: 33538412
[TBL] [Abstract][Full Text] [Related]
10. Identification of S100A8-correlated genes for prediction of disease progression in non-muscle invasive bladder cancer.
Kim SK; Kim EJ; Leem SH; Ha YS; Kim YJ; Kim WJ
BMC Cancer; 2010 Jan; 10():21. PubMed ID: 20096140
[TBL] [Abstract][Full Text] [Related]
11. Immunohistochemical based molecular subtypes of muscle-invasive bladder cancer: association with HER2 and EGFR alterations, neoadjuvant chemotherapy response and survival.
Helal DS; Darwish SA; Awad RA; Ali DA; El-Guindy DM
Diagn Pathol; 2023 Feb; 18(1):11. PubMed ID: 36737799
[TBL] [Abstract][Full Text] [Related]
12. An Oncofetal Glycosaminoglycan Modification Provides Therapeutic Access to Cisplatin-resistant Bladder Cancer.
Seiler R; Oo HZ; Tortora D; Clausen TM; Wang CK; Kumar G; Pereira MA; Ørum-Madsen MS; Agerbæk MØ; Gustavsson T; Nordmaj MA; Rich JR; Lallous N; Fazli L; Lee SS; Douglas J; Todenhöfer T; Esfandnia S; Battsogt D; Babcook JS; Al-Nakouzi N; Crabb SJ; Moskalev I; Kiss B; Davicioni E; Thalmann GN; Rennie PS; Black PC; Salanti A; Daugaard M
Eur Urol; 2017 Jul; 72(1):142-150. PubMed ID: 28408175
[TBL] [Abstract][Full Text] [Related]
13. A four-gene signature predicts disease progression in muscle invasive bladder cancer.
Kim WJ; Kim SK; Jeong P; Yun SJ; Cho IC; Kim IY; Moon SK; Um HD; Choi YH
Mol Med; 2011; 17(5-6):478-85. PubMed ID: 21308147
[TBL] [Abstract][Full Text] [Related]
14. Assessment of prognostic implication of a panel of oncogenes in bladder cancer and identification of a 3-gene signature associated with recurrence and progression risk in non-muscle-invasive bladder cancer.
Le Goux C; Vacher S; Schnitzler A; Barry Delongchamps N; Zerbib M; Peyromaure M; Sibony M; Allory Y; Bieche I; Damotte D; Pignot G
Sci Rep; 2020 Oct; 10(1):16641. PubMed ID: 33024200
[TBL] [Abstract][Full Text] [Related]
15. Epidermal Growth Factor Receptor (EGFR) Cell Expression During Adjuvant Treatment After Transurethral Resection for Non-Muscle-Invasive Bladder Cancer: A New Potential Tool to Identify Patients at Higher Risk of Disease Progression.
Di Maida F; Mari A; Scalici Gesolfo C; Cangemi A; Allegro R; Sforza S; Cocci A; Tellini R; Masieri L; Russo A; Carini M; Minervini A; Serretta V
Clin Genitourin Cancer; 2019 Aug; 17(4):e751-e758. PubMed ID: 31126772
[TBL] [Abstract][Full Text] [Related]
16. Amplification of 7p12 Is Associated with Pathologic Nonresponse to Neoadjuvant Chemotherapy in Muscle-Invasive Bladder Cancer.
Pichler R; Lindner AK; Compérat E; Obrist P; Schäfer G; Todenhöfer T; Horninger W; Culig Z; Untergasser G
Am J Pathol; 2020 Feb; 190(2):442-452. PubMed ID: 31843500
[TBL] [Abstract][Full Text] [Related]
17. MicroRNA expression profiles in muscle-invasive bladder cancer: identification of a four-microRNA signature associated with patient survival.
Xu Z; Yu YQ; Ge YZ; Zhu JG; Zhu M; Zhao YC; Xu LW; Yang XB; Geng LG; Dou QL; Jia RP
Tumour Biol; 2015 Sep; 36(10):8159-66. PubMed ID: 25990459
[TBL] [Abstract][Full Text] [Related]
18. Epidermal growth factor receptor status predicts local response to radical radiotherapy in muscle-invasive bladder cancer.
Colquhoun AJ; Sundar S; Rajjayabun PH; Griffiths TR; Symonds RP; Mellon JK
Clin Oncol (R Coll Radiol); 2006 Nov; 18(9):702-9. PubMed ID: 17100158
[TBL] [Abstract][Full Text] [Related]
19. An Epigenomic Approach to Improving Response to Neoadjuvant Cisplatin Chemotherapy in Bladder Cancer.
Xylinas E; Hassler MR; Zhuang D; Krzywinski M; Erdem Z; Robinson BD; Elemento O; Clozel T; Shariat SF
Biomolecules; 2016 Sep; 6(3):. PubMed ID: 27598218
[TBL] [Abstract][Full Text] [Related]
20. Unraveling UCA1 lncRNA prognostic utility in urothelial bladder cancer.
Avgeris M; Tsilimantou A; Levis PK; Rampias T; Papadimitriou MA; Panoutsopoulou K; Stravodimos K; Scorilas A
Carcinogenesis; 2019 Aug; 40(8):965-974. PubMed ID: 30815670
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
